MYOS RENS Technology Inc. (NASDAQ:MYOS) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday.

Shares of MYOS RENS Technology (NASDAQ:MYOS) opened at 1.41 on Friday. The stock’s 50 day moving average is $1.79 and its 200-day moving average is $2.45. The firm’s market cap is $8.24 million. MYOS RENS Technology has a 52-week low of $1.02 and a 52-week high of $6.98.

ILLEGAL ACTIVITY WARNING: “MYOS RENS Technology Inc. (MYOS) Downgraded to Strong Sell at ValuEngine” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at

MYOS RENS Technology Company Profile

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with's FREE daily email newsletter.